Allergo Journal International最新文献

{"title":"The long road from the first symptoms of mite allergy to mite-specific immunotherapy","authors":"Norbert Mülleneisen MD,&nbsp;Manfred Springob,&nbsp;Stephanie Salge,&nbsp;Annika Völkel,&nbsp;Friederike Magnet,&nbsp;Jens Callegari","doi":"10.1007/s40629-022-00230-9","DOIUrl":"10.1007/s40629-022-00230-9","url":null,"abstract":"<div><h2>Summary</h2><div><p>The path from first symptoms to initiation of allergen-specific immunotherapy (AIT) is too long in our survey, at just under 12 years. Even from diagnosis to AIT, it still takes 8.5 years. The reasons are manifold. The complaints are mostly sneezing (75%), runny and stuffy nose (65 and 63%, respectively), itching of the eyes and nose (59%), but also breathing difficulties (40%). Most of our patients were polysensitized (78%) and had asthma (63%). AIT should be considered earlier in mite allergic patients.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 8","pages":"284 - 287"},"PeriodicalIF":0.0,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43307439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tree of heaven (Ailanthus altissima) pollen—a possible new source of sensitization in Central Europe","authors":"Matthias Werchan,&nbsp;Dominik Flener,&nbsp;Karl-Christian Bergmann","doi":"10.1007/s40629-022-00228-3","DOIUrl":"10.1007/s40629-022-00228-3","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 2","pages":"53 - 55"},"PeriodicalIF":0.0,"publicationDate":"2022-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00228-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43989994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of protracted eosinopenia after a single subcutaneous dose of benralizumab","authors":"Joana Miranda MD,&nbsp;José Luís Plácido MD,&nbsp;Luís Amaral MD","doi":"10.1007/s40629-022-00227-4","DOIUrl":"10.1007/s40629-022-00227-4","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 4","pages":"112 - 113"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00227-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40386970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergens from house dust and storage mites","authors":"Susanne Vrtala","doi":"10.1007/s40629-022-00226-5","DOIUrl":"10.1007/s40629-022-00226-5","url":null,"abstract":"<div><h2>Summary</h2><div><p>House dust mites are among the most important allergy triggers worldwide. While mites of the genus <i>Dermatophagoides </i>occur almost worldwide, the tropical mite <i>Blomia tropicalis </i>and storage mites are only of importance for certain areas or groups of people. The most important allergens of <i>Dermatophagoides pteronyssinus </i>are Der p 1, Der p 2, and Der p 23 with immunoglobulin E (IgE)-binding frequencies of more than 70% and high allergenic activity. Also of importance are Der p 5, Der p 7, and Der p 21, which have IgE-binding frequencies of about 30%. According to the current state of knowledge, these six allergens are the allergens of clinical relevance which are also required for diagnosis and immunotherapy with individual components.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 8","pages":"267 - 271"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00226-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44374483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus on prophylactic treatment of hereditary angioedema","authors":"Jens Greve,&nbsp; Tamar Kinaciyan,&nbsp;Marcus Maurer,&nbsp;Barbara Dillenburger,&nbsp;Andreas Recke,&nbsp;Clemens Schöffl","doi":"10.1007/s40629-022-00223-8","DOIUrl":"10.1007/s40629-022-00223-8","url":null,"abstract":"<div><h2>Summary</h2><div><p>Hereditary angioedema (HAE) is a chronic, genetic condition which severely impacts those afflicted with intermittent recurrent vascular edema in mucosal and submucosal tissue or in the dermis and subcutis. These swellings adversely impact the wellbeing of patients, both physically and emotionally. Depending on the location, patients present to doctors in a range of disciplines, and not infrequently misdiagnoses occur, such as appendicitis or an allergy, with subsequent incorrect treatment. An HAE attack can also be life-threatening if larynx is affected. However, medications for treating the more common mast cell-induced angioedema are not effective in HAE. Correct diagnosis of the condition, which often first appears in childhood or adolescence, is therefore essential for effective treatment. De novo mutations where the family history is negative are particularly challenging here. However, a range of new treatment options can help HAE patients by preventing attacks and alleviating the burden of the disease. In this review, we summarize the symptoms experienced by patients with HAE as a result of their condition, but also as a result of misdiagnoses and incorrect treatments, as well as the role of preventive treatment (long-term prophylaxis) in improving the quality of life of those affected and their families. In addition, we provide specific information about how HAE can be detected at an early stage in order to be able to refer patients to experts as soon as possible. With reference to the recommendations of the updated WAO/EAACI guidelines (2022), we argue for a stronger role for long-term prophylaxis and the promotion of modern, patient-centered management of HAE using patient-reported outcome measures (PROMs) to manage quality of life and the burden of the disease.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 7","pages":"233 - 242"},"PeriodicalIF":0.0,"publicationDate":"2022-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00223-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43257289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS)","authors":"Anna Gschwend PhD,&nbsp;Arthur Helbling MD,&nbsp;Laurence Feldmeyer PhD,&nbsp;Ulrich Mani-Weber MD,&nbsp;Cordula Meincke MD,&nbsp;Kristine Heidemeyer MD,&nbsp;Simon Bossart MD,&nbsp;Lukas Jörg MD","doi":"10.1007/s40629-022-00224-7","DOIUrl":"10.1007/s40629-022-00224-7","url":null,"abstract":"<div><h3>Purpose</h3><p>Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe delayed drug hypersensitivity reaction with exanthema, eosinophilia, and organ manifestations. After culprit drug withdrawal, systemic corticosteroids (CS) are the most widely used treatment, often requiring high doses for months. Blocking the IL-5/IL‑5 receptor axis with mepolizumab, reslizumab, and benralizumab is a promising targeted treatment with a good safety profile and no immunosuppressive effect. The aim of this study is to summarize current experience with the anti-IL5/IL-5-receptor therapy in DRESS.</p><h3>Methods</h3><p>A retrospective analysis of all patients diagnosed with DRESS and treated with mepolizumab, reslizumab, or benralizumab in DRESS was performed. In addition, a PubMed–Medline search for publications on DRESS with anti-IL-5/IL‑5 receptor treatment was performed.</p><h3>Results</h3><p>Of the 14 cases identified, 6 patients were treated with mepolizumab, 6 with benralizumab, 1 patient with reslizumab, and 1 patient was switched from benralizumab to mepolizumab. The main indication for an IL‑5 blockade was a therapy-refractory course (7/14 [50.0%]), recurrent relapses (3/14 [21.4%]), and severe organ dysfunction (2/14 [14.3%]). In 13/14 (93%) cases, a rapid clinical improvement with suppression of eosinophilia and reduction of CS could be achieved. In all but two cases under mepolizumab (dose 100–600 mg) or reslizumab (dose according to body weight), two or more doses were necessary until resolution of DRESS. In 4/7 cases under benralizumab, a single 30 mg dose was sufficient.</p><h3>Conclusion</h3><p>Blockade of the IL-5/IL‑5 receptor axis appears to be a promising treatment in DRESS with fast clinical improvement, which may allow more rapid reduction of CS, and a good safety profile. In addition, a summary of recommendations on when to use blockade of the IL-5/IL‑5 receptor axis in DRESS treatment is provided.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 4","pages":"104 - 111"},"PeriodicalIF":0.0,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00224-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33444369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts of the 17th German Allergy Congress, Wiesbaden, 08.–10. September 2022","authors":"","doi":"10.1007/s40629-022-00225-6","DOIUrl":"10.1007/s40629-022-00225-6","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 6","pages":"194 - 232"},"PeriodicalIF":0.0,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47448140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)","authors":"Ludger Klimek,&nbsp;Ulrike Förster-Ruhrmann,&nbsp;Achim G. Beule,&nbsp;Adam M. Chaker,&nbsp;Jan Hagemann,&nbsp;Felix Klimek,&nbsp;Ingrid Casper,&nbsp;Tilman Huppertz,&nbsp;Thomas K. Hoffmann,&nbsp;Stefan Dazert,&nbsp;Thomas Deitmer,&nbsp;Heidi Olze,&nbsp;Sebastian Strieth,&nbsp;Holger Wrede,&nbsp;Wolfgang Schlenter,&nbsp;Hans-Jürgen Welkoborsky,&nbsp;Barbara Wollenberg,&nbsp;Christoph Bergmann,&nbsp;Mandy Cuevas,&nbsp;Caroline Beutner,&nbsp;Moritz Gröger,&nbsp; Sven Becker","doi":"10.1007/s40629-022-00220-x","DOIUrl":"10.1007/s40629-022-00220-x","url":null,"abstract":"<div><h2>Summary</h2><div><h3>Background</h3><p>Chronic rhinosinusitis with nasal polyps (CRSwNP), an inflammatory disease of the paranasal mucosa, is primarily characterized by type 2 inflammation. Three antibodies (dupilumab, omalizumab, and mepolizumab) are now approved for the treatment of severe CRSwNP. Documentation of disease severity during the course of treatment is essential.</p><h3>Methods</h3><p>A literature search of Medline, PubMed, and the national and international trial and guideline register, and the Cochrane Library was performed to analyze the immunology of CRSwNP and determine the evidence for the effect of dupilumab, omalizumab, and mepolizumab in this disease. This has resulted in 3 position papers prepared by our group of authors, which form the basis of this summarizing review.</p><h3>Results</h3><p>Based on the information from the international literature, recommendations for the use of dupilumab, omalizumab, and mepolizumab in CRSwNP in the German health care system are given by an expert panel.</p><h3>Conclusion</h3><p>Dupilumab, omalizumab, and mepolizumab are approved for patients 18 years of age and older with CRSwNP as add-on therapy to intranasal corticosteroids when, for dupilumab and mepolizumab, therapy with systemic corticosteroids and/or surgery does not achieve sufficient disease control. Therapy with omalizumab is indicated when therapy with intranasal corticosteroids does not result in sufficient disease control. Dedicated recommendations for the documentation of the use in the German health care system are given, which are based on the position papers of our author group already published on this topic.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 6","pages":"149 - 160"},"PeriodicalIF":0.0,"publicationDate":"2022-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00220-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43217495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Idiopathic hypereosinophilic syndrome—diagnosis and treatment","authors":"Juliana Schwaab,&nbsp;Johannes Lübke,&nbsp;Andreas Reiter,&nbsp;Georgia Metzgeroth","doi":"10.1007/s40629-022-00221-w","DOIUrl":"10.1007/s40629-022-00221-w","url":null,"abstract":"<div><p>Sustained elevation of eosinophils above 5 × 10⁹ /l in peripheral blood (PB) should prompt further investigation. Clonal eosinophilia accounts for the much smaller proportion of eosinophilias (&lt; 10%), but exclusion of such a neoplasia is prognostically and therapeutically relevant. Molecular genetic analysis from PB, cytogenetics from bone marrow, and bone marrow histology are primarily used to exclude clonal eosinophilia. Far more common is reactive eosinophilia, the cause of which may be drugs, allergies, solid tumors, lymphomas, worm infections, autoimmune diseases, or idiopathic hypereosinophilic syndrome (HES). Because of the diverse organ infiltration patterns in eosinophilia, a specific search for possible organ involvement (including heart, lung, gastrointestinal tract, kidney, skin, etc.) should be performed, depending on the patient’s symptoms. The diagnosis of HES is made when organ infiltration with consecutive dysfunction is diagnosed in persistent eosinophilia after exclusion of other causes. Therapeutically, oral corticosteroids (OSC) are used in HES. This can also be helpful in the differential diagnosis, as patients with clonal eosinophilia are usually not expected to achieve remission with OCS. When OCS requirements are high, other immunosuppressants (e.g., methotrexate [MTX], cyclophosphamide) and the interleukin (IL)-5 antagonist mepolizumab are used. In clonal eosinophilia, tyrosine kinase inhibitors are the first-line therapy, depending on the underlying genetic alteration.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 7","pages":"251 - 256"},"PeriodicalIF":0.0,"publicationDate":"2022-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00221-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44735841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In silico investigation for drug-like pharmacophores against food allergen profilins","authors":"Bhupender Singh,&nbsp;Sadaf Jan,&nbsp;Atul Kumar Upadhyay,&nbsp;Neeta Raj Sharma","doi":"10.1007/s40629-022-00222-9","DOIUrl":"10.1007/s40629-022-00222-9","url":null,"abstract":"<div><h3>Purpose</h3><p>The food allergen protein profilin is responsible for oral epithelial remodelling and hypersensitive reactions in atopic individuals. Profilins are regarded as panallergens due to their IgE cross-reactivity.</p><h3>Methods</h3><p>The present study reports a bioinformatic pipeline including multiple sequence alignment, homology modelling, molecular dynamic simulation, virtual screening and bioavailability profiling techniques for pharmacophore screening against food allergen profilins to combat associated complications.</p><h3>Results</h3><p>Tertiary structure prediction of food allergen profilins from apple, pineapple, wheat and soybean revealed their structural-level conservation accounting for their IgE cross-reactivity, and molecular dynamics for 10 ns affirmed the fitness of modelled profilin structures. By virtue of virtual screening, we have identified the best pharmacophores against food allergen profilins from apple, pineapple, wheat and soybean, exhibiting a binding energy efficiency of −8.0, −7.2, −7.5 and −10.0 kcal/mol, respectively. Lastly, the bioavailability profiles of these identified pharmacophores designate their suitability to act as orally bioavailable compounds.</p><h3>Conclusion</h3><p>This information regarding binding affinity and stability of the identified pharmacophores against food allergen profilins designates them as lead molecules for in vitro studies.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 2","pages":"38 - 46"},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00222-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48268249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}